# Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder

> **NCT06261060** · PHASE2 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 6 (estimated)

## Conditions studied

- Familial Platelet Disorder
- Hematopoietic

## Interventions

- **DRUG:** Sirolimus

## Key facts

- **NCT ID:** NCT06261060
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-20
- **Primary completion:** 2026-06-11
- **Final completion:** 2028-06-11
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-04-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06261060

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06261060, "Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06261060. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*